Sign In
Buy ZLDAF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products
09:12pm, Wednesday, 22'nd Sep 2021
Zelira Therapeutics Ltd, a leading global medicinal cannabis company, has launched its new line of CBD-based acne and skin products, RAF FIVE™. Developed in partnership with Harvard-trained and US b
Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement
09:07pm, Sunday, 19'th Sep 2021
Zelira Therapeutics Ltd has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a German subsidia
Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22
06:50pm, Tuesday, 31'st Aug 2021
Zelira Therapeutics Ltd continues to focus on the expansion of commercialisation activities and revenue generation from its new clinically tested products, with the strategy expected to lead to the la
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
09:45pm, Thursday, 29'th Jul 2021
Zelira Therapeutics Ltd has capped off the 2021 financial year with record cash receipts as it looks ahead to product launches later this year. The cannabinoid medicines developer finished the June qu
Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial
11:10pm, Sunday, 11'th Jul 2021
Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US. The cannabinoid medicines developer is set t
Zelira Therapeutics has clinical trial results of Zenivol® published in SLEEP®
10:06pm, Sunday, 20'th Jun 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is encouraged that the results of a trial in chronic insomnia patients of its proprietary cannabinoid ZLT101 formulation marketed as Zenivol
Zelira Therapeutics research demonstrates significant uptake of CBD into the brain
10:14pm, Thursday, 17'th Jun 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is buoyed that Curtin University researchers have developed a new technology that improves delivery of cannabidiol (CBD) based drugs into t
Zelira Therapeutics partners with Health House International to bring CBD toothpaste to the UK
07:43pm, Monday, 14'th Jun 2021
Zelira Therapeutics Ltd's (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) CBD-formulated toothpaste is primed to hit the UK market under an exclusive distribution agreement. The healthcare company inked the distr
Zelira Therapeutics teams up with Levin Health to trial cannabinoid treatment for chronic pain in retired athletes
10:54pm, Wednesday, 02'nd Jun 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has licensed its cannabis formulation to Levin Health Limited for an upcoming clinical trial. Levins will use the medicinal cannabis company's ZTL-10
Zelira Therapeutics launches HOPE™ range of autism spectrum disorder products in Washington DC
10:13pm, Wednesday, 05'th May 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has launched its HOPE™ range of autism spectrum disorder products in Washington DC through its partnership with Alternative Solutions LLC, a license
Zelira Therapeutics well-placed to build on considerable March quarter momentum
06:56pm, Wednesday, 21'st Apr 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) is well placed to build on the considerable momentum generated during the March quarter by launching new products and expanding into new geog
Zelira Therapeutics delivers record March quarter revenue of $225,000
07:44pm, Wednesday, 14'th Apr 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) achieved record product sales and licensing revenues of A$225,000 during the March quarter - up 249% on the prior six months. This revenue g
Zelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sector
12:41am, Thursday, 08'th Apr 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has strategically consolidated its operations to transfer the leadership of the company to its US-based team, with Dr Oludare Odumosu to assum
Zelira Therapeutics positions for future growth with transition to US-based leadership team led by Dr Oludare Odumosu
04:57pm, Sunday, 14'th Feb 2021
Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) strategic consolidation of its operations will see leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming
Zelira Therapeutics appointed to the board of US National Cannabis Roundtable
08:01pm, Wednesday, 10'th Feb 2021
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has been appointed to the board of directors of the National Cannabis Roundtable (NCR) in Washington DC, US. The company will be represented
